Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

Inclusion Criteria

• •The subject must give signed informed consent before any study-related activities.
• •The partner, if applicable, must give signed informed consent before administration of Somatuline Autogel.
• •The subject must be able to understand the protocol requirements.
• •The subject must have a clinical diagnosis of acromegaly due to pituitary tumor.
• •The subject must be treated with a long-acting somatostatin analogue with or without a dopamine agonist and have been on the current medical regimen for at least 3 months prior to screening and have IGF-1 levels no higher than 10% above the upper limit of the normal range for age and gender at the screening visit or be somatostatin analogue naïve (if the subject is treated with a dopamine agonist he/she must have been on the current dose for at least 3 months prior to screening).
• •Subjects who are treated with a dopamine agonist have to stay on their current dose for the duration of the study.
• •Switch subjects must have had their last pre-study routine clinical treatment with Sandostatin LAR between 28 and 35 days before Visit 2 (enrollment).
• •The subject must be able to store the study medication in a refrigerator in his/her own or his/her partner's home.
• •The subject must be ≥18 years of age.
• •Female subjects of childbearing potential must use adequate contraception.
• •Female subjects of childbearing potential who are taking oral contraceptives must agree to stay on their current contraceptive dose for the duration of the study.
• •The partner, if applicable, must be ≥18 years of age.